December 17, 2019

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – 17 December 2019 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraor...
Read more
December 12, 2019

Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial

Oslo, Norway, 12 December 2019 Nordic Nanovector ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractor...
Read more
December 11, 2019

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

Paris, France, Wednesday, December 11, 2019, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on d...
Read more
December 9, 2019

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

Paris, France, December 9, 2019, 7.30 am CET – The National Eye Hospital (CHNO) of the Quinze-Vingts in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR001318...
Read more
December 9, 2019

BONESUPPORTTM CERTiFy STUDY ON CERAMENT® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY

Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I cli...
Read more
December 9, 2019

Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual

December 9, 2019 Download PDF 88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median d...
Read more
December 8, 2019

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at...
Read more
December 6, 2019

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET...
Read more
December 4, 2019

Nordic Nanovector: New preclinical data offer insights into enhancing Betalutin®-based therapies in NHL

Oslo, Norway, 4 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab s...
Read more
December 2, 2019

Oncopeptides appoints Joseph Horvat as President North America

Stockholm – December 2, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopeti...
Read more